PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1568424
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1568424
Gout Therapeutics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
The Global Gout Therapeutics Market size will grow at a 7.3% CAGR from 2024 to 2032, spurred by advancements in diagnostic tools and regulatory nods.
With enhanced diagnostic methods, the timely identification of gout has become more precise, paving the way for targeted treatments. These technological strides not only bolster the detection of uric acid levels and inflammation markers but also usher in personalized therapy options. Simultaneously, regulatory bodies are greenlighting new medications and treatment protocols, broadening the therapeutic arsenal. For example, in July 2022, Horizon Therapeutics secured an expanded U.S. FDA label for Krystexxa, aiming to bolster treatment outcomes for patients grappling with uncontrolled gout. Such strides in gout therapeutics are offering more robust management solutions for challenging cases.
The market is segregated into drug class, condition, route of administration, distribution channel, and region.
In terms of drug class, the corticosteroids segment in the gout therapeutics industry is set to accrue a significant growth rate through 2032. This surge is largely attributed to the escalating demand for managing acute inflammation and pain. By dampening the immune response and curbing inflammation, corticosteroids effectively alleviate swelling and discomfort during gout flare-ups. Furthermore, ongoing research endeavors are fine-tuning dosages and administration techniques to boost efficacy while curtailing side effects.
By condition, the gout therapeutics market share from the chronic gout segment is projected to rise from 2024 to 2032. This uptick is driven by a growing preference for long-term management and flare-up prevention. Medications like xanthine oxidase inhibitors and uricosuric agents are pivotal in lowering uric acid levels, staving off urate crystal formation, and curbing inflammation. As a result, these advancements are bolstering long-term chronic gout control, minimizing daily life disruptions, and uplifting patient outcomes.
Regionally, the Europe gout therapeutics industry size is anticipated to depict a robust CAGR between 2024 and 2032, largely fueled by its aging populace. Recent trends show a shift towards more tailored treatment options, with future advancements hinting at personalized medicine and innovative therapeutic strategies. Such moves aim to address the unique needs of Europe's older demographic, promising an enhanced quality of life and more effective gout management.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of gout
- 3.2.1.2 Advancements in treatment options
- 3.2.1.3 Rising awareness towards early gout diagnosis
- 3.2.1.4 Dietary and lifestyle shifts
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High cost of gout treatment
- 3.2.2.2 Side effects and safety concerns
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
- 3.6 Pricing analysis, 2023
- 3.6.1 By region
- 3.6.2 By key player
- 3.7 Future market trends
- 3.8 Porter's analysis
- 3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Non-steroidal anti-inflammatory drugs (NSAIDs)
- 5.3 Corticosteroids
- 5.4 Colchicine
- 5.5 Urate-lowering agents
- 5.6 Other drug classes
Chapter 6 Market Estimates and Forecast, By Condition, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Acute gout
- 6.3 Chronic gout
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Oral
- 7.3 Parenteral
- 7.4 Other routes of administration
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacy
- 8.3 Retail pharmacy
- 8.4 Online pharmacy
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Astrazeneca Plc
- 10.2 Addex Therapeutics
- 10.3 Abbvie Inc.
- 10.4 Amgen Inc.
- 10.5 Boehringer Ingelheim International GmbH
- 10.6 GSK plc
- 10.7 Merck and Co., Inc
- 10.8 Novartis AG
- 10.9 Pfizer Inc
- 10.10 Regeneron Pharmaceuticals, Inc.
- 10.11 Sun Pharmaceutical Industries Ltd.
- 10.12 Takeda Pharmaceutical Company Ltd.
- 10.13 Teva Pharmaceuticals Industries Ltd.
- 10.14 Teijin Limited
- 10.15 Zydus Lifesciences Limited
